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Cardiac Hypertrophy, Accessory Pathway,
and Conduction SystemDisease in an Adolescent
The PRKAG2 Cardiac Syndrome
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Laura Vitali Serdoz, MD,* Massimo Zecchin, MD,* Giovanni Maria Severini, PHD,y
Luisa Mestroni, MD,z Antonio Di Chiara, MD,x Gianfranco Sinagra, MD*
Trieste and Tolmezzo, Italy; and Aurora, Colorado17-year-old asymptomatic boy was referred to our hospital for family screening because ofAhis father’s unexplained left ventricular hypertrophy (LVH). The father receiveda pacemaker at 35 years of age for sick sinus syndrome. The electrocardiogram showed
LVH and a short PR interval and seemed to show a delta-wave (A). Echocardiography showed
mild asymmetrical LVH with posterolateral distribution (B, Online Video 1). Cardiac magnetic
resonance imaging (C, Online Video 2) conﬁrmed asymmetric LVH (maximal wall thickness of
13 mm). A few weeks later, he presented to the emergency department with sudden onset of
palpitations. The electrocardiogram showed a supraventricular tachycardia with aberrant
conduction (D). An electrophysiological study showed a posteroseptal accessory pathway, which
was successfully ablated. Before the procedure, an intermittent third-degree atrioventricular block
was observed (E), and a pacemaker was subsequently implanted. Genetic testing identiﬁed
a missense mutation in the protein kinase, AMP-activated, noncatalytic, gamma-2 (PRKAG2)
gene leading to an Arg302Glu substitution. As in this case, the PRKAG2 autosomal dominant
cardiac syndrome may be commonly characterized by LVH, an accessory pathway, and progression
to conduction disease requiring implantation of a pacemaker (1).
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